Merck KGaA is dropping a heart drug from its Silence deal after a rival's trial failed
Merck KGaA will not pursue an advanced study of zerlasiran, which lowers a cholesterol particle, after Novartis ended a similar drug
We haven't written up this one. Quartz has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.